Modelling the lymphatic metastatic progression pathways of OPSCC from multi-institutional datasets.

Ludwig, Roman; Schubert, Adrian Daniel; Barbatei, Dorothea; Bauwens, Lauence; Hoffmann, Jean-Marc; Werlen, Sandrine; Elicin, Olgun; Dettmer, Matthias; Zrounba, Philippe; Pouymayou, Bertrand; Balermpas, Panagiotis; Grégoire, Vincent; Giger, Roland; Unkelbach, Jan (2024). Modelling the lymphatic metastatic progression pathways of OPSCC from multi-institutional datasets. Scientific Reports, 14(15750) Nature Publishing Group 10.1038/s41598-024-66012-1

Preview

Text s41598-024-66012-1.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (4MB) | Preview

The elective clinical target volume (CTV-N) in oropharyngeal squamous cell carcinoma (OPSCC) is currently based mostly on the prevalence of lymph node metastases in different lymph node levels (LNLs) for a given primary tumor location. We present a probabilistic model for ipsilateral lymphatic spread that can quantify the microscopic nodal involvement risk based on an individual patient's T-category and clinical involvement of LNLs at diagnosis. We extend a previously published hidden Markov model (HMM), which models the LNLs (I, II, III, IV, V, and VII) as hidden binary random variables (RVs). Each represents a patient's true state of lymphatic involvement. Clinical involvement at diagnosis represents the observed binary RVs linked to the true state via sensitivity and specificity. The primary tumor and the hidden RVs are connected in a graph. Each edge represents the conditional probability of metastatic spread per abstract time-step, given disease at the edge's starting node. To learn these probabilities, we draw Markov chain Monte Carlo samples from the likelihood of a dataset (686 OPSCC patients) from three institutions. We compute the model evidence using thermodynamic integration for different graphs to determine which describes the data best.The graph maximizing the model evidence connects the tumor to each LNL and the LNLs I through V in order. It predicts the risk of occult disease in level IV is below 5% if level III is clinically negative, and that the risk of occult disease in level V is below 5% except for advanced T-category (T3 and T4) patients with clinical involvement of levels II, III, and IV. The provided statistical model of nodal involvement in OPSCC patients trained on multi-institutional data may guide the design of clinical trials on volume-deescalated treatment of OPSCC and contribute to more personal guidelines on elective nodal treatment.

Interest & Impact

Downloads

5 since deposited on 09 Jul 2024
5 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item